Company intelligence / Profile preview

TechnoDerma Medicines Inc.

Chengdu, Sichuan Sheng, Chinatkskin.com ↗

Ownership: Private
Development stage: Phase 2

Overview

TechnoDerma has completed positive Phase 2a proof-of-concept trials for its topical JAK1/TYK2 inhibitor TDM-180935 in atopic dermatitis, demonstrating strong efficacy and favorable safety with minimal systemic exposure. Its first-in-class small molecule thyromimetic TDM-105795 for androgenetic alopecia has also successfully completed Phase 2a clinical testing. Additional programs are in preclinical or early clinical stages targeting psoriasis and lupus erythematosus. The company expects to advance a novel oral drug program into Phase 1 in 2025.

Therapeutic areas: ImmunologyDermatology
Modalities: small molecules
Industry: Biotech

Drug pipeline

3 assets

tdm-180935

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on TechnoDerma Medicines Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TechnoDerma Medicines Inc..

Explore the full profile